(Q30659100)

26 June 2017

title

Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

26 June 2017

0 references

0 references

author name string

Paul L McCormack

series ordinal

1

1 reference

26 June 2017

publication date

1 September 2013

1 reference

26 June 2017

1 reference

26 June 2017

volume

73

1 reference

26 June 2017

issue

13

1 reference

26 June 2017

page(s)

1463-1481

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

26 June 2017

1 reference

The immunopathology of multiple sclerosis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Natural history of multiple sclerosis with childhood onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

International consensus statement on the use of disease-modifying agents in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Disease-modifying agents for multiple sclerosis: recent advances and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Integrin signalling and function in immune cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Characterization of anti-natalizumab antibodies in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Best practice in the use of natalizumab in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Drugs in development for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Natural, innate improvements in multiple sclerosis disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Pharmacoeconomic considerations in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0102-7

Clinically significant liver injury in patients treated with natalizumab

21 January 2018

1 reference

12 December 2020

Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months

1 reference

12 December 2020

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

1 reference

12 December 2020

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden

1 reference

12 December 2020

Natalizumab treatment during pregnancy - effects on the neonatal immune system

1 reference

12 December 2020

Central nervous system immune surveillance: on natalizumab, dendritic cells, and dangerous immune privilege

1 reference

12 December 2020

Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis

1 reference

12 December 2020

Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

1 reference

12 December 2020

Prediction of antibody persistency from antibody titres to natalizumab

1 reference

12 December 2020

Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients

1 reference

12 December 2020

1 reference

12 December 2020

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

1 reference

12 December 2020

Natalizumab treatment reduces endothelial activity in MS patients

1 reference

12 December 2020

Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy

1 reference

12 December 2020

Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

1 reference

12 December 2020

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

12 December 2020

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

1 reference

12 December 2020

More on melanoma with transdifferentiation

1 reference

12 December 2020

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

12 December 2020

10.1007/S40265-013-0102-7

Identifiers

DOI

1 reference

Dimensions Publication ID

26 June 2017

1049074980

0 references

1 reference